Medicine guide
Riprazo HCT
·
- Prescription status not stated
- Heart, blood pressure and circulation
- Active substance
- Aliskiren;hydrochlorothiazide
- Made by
- Novartis Europharm Ltd.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment of essential hypertension in adults. Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Novartis Europharm Ltd. |
|---|---|
| Active substance | Aliskiren;hydrochlorothiazide |
| Used in | Heart, blood pressure and circulation |
| Classification | C09XA52 · Heart, blood pressure and circulation |
| Authorised on | 2011-04-13 |
| Last updated by the regulator | 2012-09-20 |
| EMA product number | EMEA/H/C/002420 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.